The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Poll|October 25, 2023
POLL: What Topic Are You Most Looking Forward to at SDPA Fall 2023?
Author(s)Emma Andrus, Associate Editor
Click here to answer today's poll.
Advertisement
What topic are you most looking forward to at SDPA?
What are you most looking forward to as the 2023 Society of Dermatology Physician Assistants (SDPA) Fall Dermatology Conference kicks off tomorrow in Nashville, Tennessee?
Share with us by answering our poll.
Not sure what sessions are going to peak your interest yet? Be sure to check out our
Are you attending the conference and want to share your insights with our team while we are live and on-site in the Music City? Email our team at
See you in Nashville!
Make sure to keep up to date with the latest in coverage from the conference and subscribe to Dermatology Times to receive daily email updates .
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
FDA Revises TB Evaluation Guidance for SKYRIZI
4
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
5